Decision-analytical modelling in health-care economic evaluations

European Journal of Health Economics

Volumn 9, Issue 4, 2008, Pages 313-323

  Sun, Xin ^a,b   Faunce, Thomas ^c  

^a MCMASTER UNIVERSITY   (Canada)

^b SICHUAN UNIVERSITY   (China)

^c The Australian National University   (Australia)

Author keywords

Cost effectiveness analysis; Decision analysis; Economic evaluation; Markov model

Indexed keywords

CONCEPTUAL FRAMEWORK; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DEVELOPMENT; EVIDENCE BASED PRACTICE; HEALTH CARE COST; HEALTH CARE PRACTICE; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HEPATITIS B; MEDICAL TECHNOLOGY; METHODOLOGY; MONTE CARLO METHOD; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROBABILITY; REVIEW; STATISTICAL MODEL; STRENGTH; TREATMENT OUTCOME;

COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; HEALTH CARE COSTS; HEPATITIS B, CHRONIC; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; MARKOV CHAINS; MODELS, ECONOMIC; MODELS, STATISTICAL; MONTE CARLO METHOD; UNCERTAINTY;

EID: 53849090998     PISSN: 16187598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10198-007-0078-x     Document Type: Review

References (39)

1. X. Sun E. Orlewska Y.P. Li G. Cheng H. Yang 2006 Methods for economic evaluation of marketed medicines II: Conducting primary economic evaluation Chin J Evid Based Med 6 218 223
2. Commonwealth Department of Health Housing and Community Services: Guidelines for the Pharmaceutical Industry on Preparation of Submissions to the Pharmaceutical Benefits Advisory Committee. Including Major Submissions Involving Economic Analyses (draft). Canberra (2006)
3. Food and Drug Administration: Principles for the Review of Pharmacoeconomic Promotion. Rockville: FDA (1995)
4. A. Brennan R. Akehurst 2000 Modelling in health economic evaluation: What is its place? What is its value? Pharmacoeconomics 17 5 445 459
5. M.J. Buxton M.F. Drummond B.A. Van Hout R.L. Prince T.A. Sheldon T. Szucs M. Vray 1997 Modelling in economic evaluation: an unavoidable fact of life Health Econ 6 217 227
6. A. Brennan R. Akehurst 2000 Modelling in health economic evaluation. What is its place? What is its value? Pharmacoeconomics 17 445 459
7. M. Sculpher M. Drummond M. Buxton 1997 The interactive use of economic evaluation as part of the process of health technology assessment J Health Serv Res Policy 2 26 30
8. Chilcott, J.B., Brennan, A., Booth, A., Karnon, J., Tappenden, P.: The role of modelling in prioritising and planning clinical trials. Health Technol Assess 7, 1-125 (2003)
9. J. Karnon 2003 Alternative decision modelling techniques for the evaluation of health care technologies: Markov processes versus discrete event simulation Health Econ 12 837 848
10. E. Orlewska 2002 The cost-effectiveness of alternative therapeutic strategies for the management of chronic hepatitis B in Poland Value Health 5 405 421
11. J.L. Wright H. Wessells A.B. Nathens W. Hollingworth 2006 What is the most cost-effective treatment for 1 to 2-cm bulbar urethral strictures: societal approach using decision analysis Urology 67 889 893
12. Chambers, M.G., Koch, P., Hutton, J.: Development of a decision-analytic model of stroke care in the United States and Europe. Value Health 5, 82-97 (2002)
13. Spiegelhalter, D.J., Abrams, K.R., Myles, J.P.: Bayesian Approaches to Clinical Trials and Health-Care Evaluation. London: Wiley (2004)
14. J.S. Breese 1992 Construction of belief and decision networks Comput Intel 8 624 647
15. Powell 2003 The Delphi technique: myths and realities J Adv Nurs 41 376 382
16. B.C. van Steenkiste J.E. Jacobs N.M. Verheijen J.H. Levelink B.J.A.M. Bottema 2002 A Delphi technique as a method for selecting the content of an electronic patient record for asthma Int J Med Inf 65 7 16
17. Salomon, J.A., Murray, C.J.L.: A multi-method approach to measuring health-state valuations. Health Econ 13, 281-290 (2004)
18. Brazier, J., Deverill, M., Green, C., Harper, R., Booth, A.: A review of the use of health status measures in economic evaluation. Health Technol Assess 3 (9) (1999)
19. A. Briggs M. Sculpher M. Buxton 1994 Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis Health Econ 3 95 104
20. H.A. Briggs 2000 Handling uncertainty in cost-effectiveness models Pharmacoeconomics 17 479 500
21. M.J.C. Nuijten 2004 Incorporation of statistical uncertainty in health economic modelling studies using second-order Monte Carlo simulations Pharmacoeconomics 22 759 769
22. Philips, Z., Ginnelly, L., Sculpher, M., Claxton, K., Golder, S., Riemsma, R.: Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess 8(36) (2004)
23. F.A. Sonnenberg M.S. Roberts J. Tsevat J.B. Wong M. Barry D. Ken 1994 Toward a peer review process for medical decision analysis models Med Care 32 JS52 JS64
24. A. Briggs M. Sculpher 1998 An introduction to Markov modelling for economic evaluation Pharmacoeconomics. 13 397 409
25. R. Shamir O. Hernell M. Leshno 2006 Cost-effectiveness analysis of screening for celiac disease in the adult population Med Decis Making 26 282 293
26. CDC Diabetes Cost-effectiveness Group 2002 Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes JAMA 87 2542 2551
27. Canadian Coordinating Office for Health Technology Assessment: Guidelines for economic evaluation of pharmaceuticals: Canada, 3rd edn. Ottawa: Canadian Agency for Drugs and Technologies in Health (2006)
28. M.C. Weistein B. O'Brien J. Hornberger J. Jackson M. Johannesson C. McCabe 2003 Principles of good practice for decision analytic modeling in health-care evaluation: Report of the ISPOR task force on good research practices-modeling studies Value Health 6 9 17
29. Manca, A., Rice, N., Sculpher, M.J., Briggs, A.H.: Assessing generalisability by location in trial-based cost-effectiveness analysis: the use of multilevel models. Health Econ 14, 471-485 (2005)
30. P.D. Pharoah W. Hollingworth 1996 Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population BMJ 312 1443 1448
31. M.J.C. Nuijten M. Hardens 1997 Measuring sensitivity in pharmacoeconomic studies: an integration of point-sensitivity and range sensitivity Pharmacoeconomics 12 555 564
32. D.F. Heitjan H. Li 2004 Bayesian estimation of cost-effectiveness: an importance-sampling approach Health Econ 13 191 198
33. D.J. Vanness W.R. Kim 2002 Bayesian estimation, simulation and uncertainty analysis: the cost-effectiveness of ganciclovir prophylaxis in liver transplantation Health Econ 11 551 566
34. Briggs, A.H., Gray, A.M.: Handling uncertainty when performing economic evaluation of healthcare interventions. Health Technol Assess 3(2) (1999)
35. A.A. Stinnett J. Mullahy 1998 Net health benefits: a new framework for the analysis of uncertainty in cost effectiveness analysis Med Decis Making 18 Suppl 2 S65 S80
36. A. Gafni S. Birch 1993 Guidelines for the adoption of new technologies: a prescription for uncontrolled growth in expenditures and how to avoid the problem Can Med Assoc J 148 913 917
37. E. Fenwick D.A. Marshall A.R. Levy G. Nichol 2006 Using and interpreting cost-effectiveness acceptability curves: An example using data from a trial of management strategies for atrial fibrillation BMC Health Serv Res 6 52
38. P.P. Sendi A.H. Briggs 2001 Affordability and cost-effectiveness: Decision-making on the cost-effectiveness plane Health Econ 10 675 680
39. M.V. Bala J.A. Mauskopf 2006 Optimal assignment of treatments to health states using a Markov decision model: an introduction to basic concepts Pharmacoeconomics 24 345 354